New hope for tough blood cancers: AC676 enters human testing
NCT ID NCT05780034
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like CLL, MCL, or DLBCL) that have returned or stopped responding to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the body and whether it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
-
Swedish Cancer Institute
RECRUITINGSeattle, Washington, 98104, United States
-
Tennessee Oncology
WITHDRAWNNashville, Tennessee, 37302, United States
-
The Ohio State University - The James Cancer Hospital and Solove Research Institute
RECRUITINGColumbus, Ohio, 43210, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.